Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-06-30FDA Approved: QUETIAPINE — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for quetiapine from Accord Healthcare Inc. (ANDA 202152).
-
FDA approval · 2017-06-30FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for quetiapine fumarate (Quetiapine) by BluePoint Laboratories under an existing ANDA. This represen…
-
FDA approval · 2017-06-30FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Alembic Pharmaceuticals Limited)
The FDA approved a supplemental application for a generic quetiapine fumarate by Alembic Pharmaceuticals Limited.
-
FDA approval · 2017-06-30FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for Macleods Pharmaceuticals Limited to market quetiapine fumarate. The approval covers a generic ve…
-
CLINICAL_TRIALS trial_result · 2017-06-29Clinical Trial Update: Staccato Loxapine in Agitated Patients With Schizophrenia [Phase 3]
Phase 3 trial results for Staccato Loxapine in agitation associated with schizophrenia have been completed and results posted in 2017.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-06-28Clinical Trial Update: A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia [Phase 2, Phase 3]
A Phase 2/3 clinical trial update on aripiprazole in pediatric patients with schizophrenia. The study has completed and results were posted …
-
CLINICAL_TRIALS trial_result · 2017-06-28Clinical Trial Update: A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia [Phase 3]
A Phase 3 long-term study of aripiprazole in pediatric patients with schizophrenia has completed, with results posted in 2017.
-
CLINICAL_TRIALS research · 2017-06-26Clinical Trial Update: A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310) [Phase 3]
This entry reports the completion of a Phase 3 study evaluating RO4917838 in participants with persistent, predominantly negative symptoms o…
-
CLINICAL_TRIALS trial_result · 2017-06-23Clinical Trial Update: Psychosocial Intervention to Reduce Self-stigma and Improve Quality of Life Among People With Mental Illness in Chile [NA]
The University of Chile conducted a completed clinical trial evaluating a psychosocial intervention to reduce self-stigma and improve qualit…
-
FDA label_change · 2017-06-22FDA Approved: QUETIAPINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves Teva's supplemental application for quetiapine (generic), updating the drug's labeling under the approved ANDA.
-
FDA approval · 2017-06-22FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for quetiapine fumarate by Hikma Pharmaceuticals USA Inc., representing a new or updated approval fo…
-
CLINICAL_TRIALS research · 2017-06-22Clinical Trial Update: Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects [Phase 1]
Phase 1 study evaluating pharmacokinetics, the effect of food, safety and tolerability of a new tablet formulation of GSK1144814 in healthy …
-
CLINICAL_TRIALS trial_result · 2017-06-20Clinical Trial Update: A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers. [Phase 1]
Phase I sequential-cohort study in healthy male volunteers to determine the maximum tolerated dose; results were posted in 2017. Sponsor: Ne…
-
CLINICAL_TRIALS trial_result · 2017-06-20Clinical Trial Update: A Repeat Dose Positron Emission Tomography Study With GSK1144814 [Phase 1]
A completed Phase 1 repeat-dose PET imaging study evaluating GSK1144814 in schizophrenia.
-
CLINICAL_TRIALS research · 2017-06-20Clinical Trial Update: Financial Incentives to Improve Acceptance of Antipsychotic Injections [NA]
This clinical trial update explores using financial incentives to improve acceptance of antipsychotic injections in patients with schizophre…
-
CLINICAL_TRIALS trial_result · 2017-06-16Clinical Trial Update: Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study [NA]
Proteus Digital Health completed a psychiatry trial using the Event Marker ingestible sensor to trigger an event recorder in patients with b…
-
FDA approval · 2017-06-15FDA Approved: INVEGA SUSTENNA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for INVEGA SUSTENNA (paliperidone palmitate) submitted by Janssen Pharmaceuticals to modify or expan…
-
CLINICAL_TRIALS trial_result · 2017-06-09Clinical Trial Update: Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients [NA]
Clinical trial investigating adjunctive minocycline in patients with schizophrenia treated with clozapine has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-06-08Clinical Trial Update: Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia [Phase 2]
Phase 2 clinical trial evaluating cannabidiol for cognitive dysfunction in schizophrenia has completed. Results were posted in 2017-06-08.
-
CLINICAL_TRIALS trial_result · 2017-06-07Clinical Trial Update: N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis [Phase 2]
Phase 2 trial of N-acetylcysteine in early-phase schizophrenia spectrum psychosis completed; results were posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-06-07Clinical Trial Update: Evaluation of QTc Interval by Continuous Holter ECG Recording in Antipsychotic Drug-treated Patients With Schizophrenia [NA]
A completed clinical trial evaluated QTc interval changes using continuous Holter ECG in patients treated with antipsychotic drugs for schiz…
-
CLINICAL_TRIALS trial_result · 2017-06-07Clinical Trial Update: A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics [Phase 1]
A completed Phase 1 study evaluating the effects of RO5545965 in participants with negative symptoms of schizophrenia treated with antipsych…
-
CLINICAL_TRIALS trial_result · 2017-06-07Clinical Trial Update: Serotonin 1A Agonists and Cognition in Schizophrenia [Phase 3]
The document reports the completion of a Phase 3 trial evaluating a serotonin 1A agonist's effect on cognition in people with schizophrenia …
-
CLINICAL_TRIALS trial_result · 2017-06-06Clinical Trial Update: High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms [Phase 3]
Phase 3 trial comparing high-dose oral ziprasidone to conventional dosing in participants with residual schizophrenia symptoms; results have…
-
CLINICAL_TRIALS trial_result · 2017-06-06Clinical Trial Update: Life Goals Behavioral Change to Improve Outcomes for Veterans With Serious Mental Illness [NA]
Clinical trial update for a VA life-goals behavioral-change program aimed at improving outcomes for veterans with serious mental illness.